Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension )

N/ACompletedNCT00526708

AstraZeneca5,000 enrolled

Overview

To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with hypertension.

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

Dyslipidemia Hypertension

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on clinical grounds and fulfil the following criteria 1. Over 18 years of age 2. Currently or previously diagnosed with hypertension and receiving medical care Exclusion Criteria: 1. Patients already taking other hyperlipidemic agents 2. Patients who do not fulfil the indication criteria for statin therapy 3. Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data

Locations (3)

Research Site

Seoul, Jongro-gu, South Korea

Research Site

Seoul, Kangnam-gu, South Korea

Research Site

Seoul, Songpa-gu, South Korea

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.